Vital Signs: Asthma Prevalence, Disease Characteristics, and Self-Management Education -- United States, 2001-2009

Zahran, Hatice S.; Bailey, Cathy; Garbe, Paul
May 2011
MMWR: Morbidity & Mortality Weekly Report;5/6/2011, Vol. 60 Issue 17, p547
Background: Most persons with asthma can be symptom-free if they receive appropriate medical care, use inhaled corticosteroids when prescribed, and modify their environment to reduce or eliminate exposure to allergens and irritants. This report reviews recent progress in managing asthma and reducing its prevalence in the United States. Methods: CDC analyzed asthma data from the 2001-2009 National Health Interview Survey concerning children and adults, and from the 2001, 2005, and 2009 state-based Behavioral Risk Factor Surveillance System concerning adults. Results: Among persons of all ages, the prevalence of asthma increased from 7.3% (20.3 million persons) in 2001 to 8.2% (24.6 million persons) in 2009, a 12.3% increase. Prevalence among children (persons aged <18 years) was 9.6%, and was highest among poor children (13.5%) and among non-Hispanic black children (17.0%). Prevalence among adults was 7.7%, and was greatest in women (9.7%) and in adults who were poor (10.6%). More uninsured persons with asthma than insured could not afford to buy prescription medications (40.3% versus 11.5%), and fewer uninsured persons reported seeing or talking with a primary-care physician (58.8% versus 85.6%) or specialist (19.5% versus 36.9%). Among persons with asthma, 34.2% reported being given a written asthma action plan, and 68.1% had been taught the appropriate response to symptoms of an asthma attack. Only about one third of children or adults were using long-term control medicine such as inhaled corticosteroids at the time of the survey. Conclusions and Comment: Persons with asthma need to have access to health care and appropriate medications and use them. They also need to learn self-management skills and practice evidence-based interventions that reduce environmental risk factors.


Related Articles

  • EDITORS' CHOICE. Stephenson, Paul; Sheikh, Aziz // Primary Care Respiratory Journal;Mar2013, Vol. 22 Issue 1, piii 

    An introduction is presented in which the editors discuss various reports within the issue on topics including the risk and benefit of inhaled corticosteroids (ICS) in the treatment of chronic obstructive pulmonary disease (COPD) by Price and colleagues, trend in age-adjusted prevalence of...

  • Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma. Koopmans, J. G.; Lulfer, R.; Jansen, H. M.; Van Der Zee, J. S. // Thorax;Apr2006, Vol. 61 Issue 4, p306 

    Background: Addition of the long acting β2 agonist salmeterol to inhaled corticosteroids leads to better symptomatic asthma control than increasing the dose of inhaled corticosteroids. However, little is known about the long term effects of adding salmeterol on the asthmatic inflammatory...

  • Diagnosing and treating skin conditions in the elderly. Scalf, Leigh Ann; Shenefelt, Philip D. // Geriatrics;Jun2007, Vol. 62 Issue 6, p14 

    Contact dermatitis is a significant cause of skin disease In geriatric patients. We discuss factors that predispose older adults to contact dermatitis, such as changes in barrier function and types of commonly contacted irritants and allergens. Geriatric risk for allergic contact dermatitis...

  • Asthmatics' risk of invasive pneumococcal disease is elevated. Burke, Michael G. // Contemporary Pediatrics;Jul2005, Vol. 22 Issue 7, p16 

    This article discusses research being done on the association between asthma and the risk of invasive pneumococcal disease. The article references a study by T. R. Talbot and colleagues published in a 2005 issue of "New England Journal of Medicine." Investigators examined this association in...

  • Education: Journals watch.  // GP: General Practitioner;3/17/2014, p3 

    The article presents abstracts on medical topics which include the risk for atherosclerosis and cardiovascular disease (CVC) due to obstructive sleep apnoea (OSA), inhaled corticosteroids for the management of asthma, and the risk of statins for diabetes.

  • Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Andréjak, Claire; Nielsen, Rikke; Thomsen, Vibeke Ø; Duhaut, Pierre; Sørensen, Henrik Toft; Thomsen, Reimar Wernich // Thorax;Mar2013, Vol. 68 Issue 3, p256 

    Background Chronic respiratory disease and inhaled corticosteroid (ICS) therapy for chronic obstructive pulmonary disease (COPD) increase the risk of pneumonia. Few data are available on the association of these risk factors with non-tuberculous mycobacterial (NTM) pulmonary disease. Methods...

  • Care of asthma patients in relation to guidelines. Broder, Michael S.; Chang, Eunice Y.; Sapra, Sandhya // Allergy & Asthma Proceedings;Nov/Dec2010, Vol. 31 Issue 6, p452 

    Clinical asthma care may have to change to be brought in line with Expert Panel Report 3 (EPR3) guidelines, which recommend increased intensity of therapy (steps) to treat uncontrolled asthma. This study determined if asthma therapy steps can be identified using claims data and if patients have...

  • Use of inhaled corticosteroids during the first trimester of pregnancy and the risk of congenital malformations among women with asthma. Blais, Lucie; Beauchesne, Marie-France; Rey, Évelyne; Malo, Jean-Luc; Forget, Amélie // Thorax;Apr2007, Vol. 62 Issue 4, p320 

    Aim: To investigate whether the maternal use of different doses of inhaled corticosteroids (ICSs) during the first trimester of pregnancy for the treatment of asthma increases the risk of congenital malformations in the offspring. Methods: From the linkage of three administrative Canadian...

  • Expert Panel Report 3: A Look Two Years After Release. Kallstrom, Thomas J. // AARC Times;Aug2009, Vol. 33 Issue 8, p5 

    The article discusses the "Guidelines Implementation Panel Report for: Expert Panel Report 3--Guidelines for the Diagnosis and Management of Asthma," or the GIP Report. It cites the six components of the document, namely inhaled corticosteroids, asthma control, written asthma action plan,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics